Navigation Links
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
Date:6/29/2009

MISSISSAUGA, ON, June 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that YM's subsidiary, CIMYM BioSciences Inc. and Oncoscience AG have resolved the issues between the companies in a cooperative effort. CIMYM BioSciences has formally notified Oncoscience that it no longer intends to submit its application to the London Court of International Arbitration for resolution of the matters previously in dispute.

"We are pleased that CIMYM BioSciences and Oncoscience have resolved their differences amicably at a minimal cost to either party and that each are committed to cooperate fully in moving nimotuzumab forward clinically with all due deliberate speed," said David Allan, Chairman and CEO of YM BioSciences. "The late-stage European clinical program Oncoscience is undertaking contributes significantly to the broad program being advanced by the network of cooperative relationships dedicated to the development of this important cancer drug globally."

"Its unique safety profile and efficacy make nimotuzumab a very promising and innovative treatment option with the potential to maintain a high quality of life for patients suffering from a number of different cancer indications," added Ferdinand Bach, CEO of Oncoscience. "I am delighted that we may now focus our combined resources exclusively on the contribution to the clinical program being undertaken globally for this promising drug. Recruitment of our Phase III trial in newly diagnosed pediatric pontine glioma has been concluded and we anticipate that recruitment in our randomised Phase III trial in adult glioblastoma grade IV will be completed in 2009. We are confident that data from these tri
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Balaton, MN (PRWEB) April 27, 2015 ... into an agreement with Texas A&M University for the ... referred to as super-intensive raceway systems. The license agreement ... Dr. Addison Lawrence, extends to countries such as China, ... United Kingdom. , “We have had inquires from ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
(Date:4/27/2015)... -- Together with its customers, Elekta raised EUR 30,575 (USD ... Barcelona . The funds will be donated to ... improve cancer care, specifically radiation oncology care, around the ... should be denied potentially life-saving treatment simply because the ... and clinics around the world to take care of ...
(Date:4/27/2015)... 2015 Elsevier , a world-leading ... and Qatar University Research Office   have announced the winners ... The awards ceremony, held last week at Qatar ... by more than 40 guests representing Qatar,s ... Professor Sheikha Abdulla Al-Misnad , President of ...
Breaking Biology Technology:tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5
... (Nasdaq: QCOR ) today announced that Standard & ... 600 Index effective after the close of the U.S. financial ... in the S&P SmallCap 600 Index reflects our consistent financial ... investment community as we continue our efforts to grow sales ...
... Lewis, assistant professor in the Department of Materials Science ... prestigious Faculty Early Career Development Award (CAREER) from the ... the projected five-year, $630,000 award to understand how materials ... an outstanding researcher and academic, and we are exceptionally ...
... 2011 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... On-line Forum on Thursday, February 17, 2011 at 11:30 ... the audio webcast with slide presentation at: www.transgenomic.com ...
Cached Biology Technology:Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index 2Rensselaer professor Daniel Lewis receives NSF CAREER Award 2Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 2Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 3
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... An individual,s personality can have a big effect ... while others find novel situations stressful which can be ... discovering that animals are no different. , A ... Environment Department at the University of York has added ...
... international team of scientists, led by the Institute for Ocean ... to determine that groups of dusky sharks ( Carcharhinus obscurus ... different coastal regions across the globe are separate populations of ... exploited for the shark fin trade, which claims tens of ...
... A Philadelphia botanist who has studied rare plants for 50 years, ... for him is finally getting his due, but with a barely ... Dr. Alfred "Ernie" Schuyler, emeritus curator of botany at the ... recently was honored when a colleague discovered a new species of ...
Cached Biology News:Animals have personalities, too 2Scientists can track origin of shark fins using 'zip codes' in their DNA 2Scientists can track origin of shark fins using 'zip codes' in their DNA 3Rare Pennsylvania fungus is named for Philadelphia botanist 2
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: